Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

ClinicalTrials.gov ID: NCT01525615

Public ClinicalTrials.gov record NCT01525615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 8:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]

Study identification

NCT ID
NCT01525615
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
404 participants

Conditions and interventions

Interventions

  • Respimat inhaler Device
  • tiotropium+olodaterol (low dose) Drug
  • tiotropium + olodaterol (high dose) Drug
  • placebo to tiotropium+olodaterol Drug

Device · Drug

Eligibility (public fields only)

Age range
40 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2012
Primary completion
Aug 31, 2013
Completion
Aug 31, 2013
Last update posted
Aug 28, 2016

2012 – 2013

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
1237.15.01503 Boehringer Ingelheim Investigational Site Torrance California
1237.15.01512 Boehringer Ingelheim Investigational Site Hartford Connecticut
1237.15.01506 Boehringer Ingelheim Investigational Site Springfield Illinois
1237.15.01507 Boehringer Ingelheim Investigational Site Iowa City Iowa
1237.15.01504 Boehringer Ingelheim Investigational Site Livonia Michigan
1237.15.01511 Boehringer Ingelheim Investigational Site Saint Charles Missouri
1237.15.01509 Boehringer Ingelheim Investigational Site Lebanon New Hampshire
1237.15.01513 Boehringer Ingelheim Investigational Site Charlotte North Carolina
1237.15.01514 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1237.15.01516 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1237.15.01508 Boehringer Ingelheim Investigational Site Easley South Carolina
1237.15.01501 Boehringer Ingelheim Investigational Site Greenville South Carolina
1237.15.01505 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1237.15.01502 Boehringer Ingelheim Investigational Site Union South Carolina
1237.15.01510 Boehringer Ingelheim Investigational Site Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01525615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 28, 2016 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01525615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →